ADC Therapeutics SA (ADCT) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-03-10
How it makes money
It earns revenue from selling ZYNLONTA to US healthcare providers, with profit depending primarily on patient demand, therapy duration, and net pricing.
Revenue is generated through the sale of its sole approved product, ZYNLONTA, within the United States. Net sales are determined by the gross price minus deductions for government rebates, chargebacks, and other administrative fees. Future earnings rely on its ability to expand indications into earlier lines of therapy for DLBCL and indolent lymphomas.
What protects it: the moat
Management claims it protects its position through intellectual property and specialized manufacturing capabilities, though it faces intense competition from other therapies.
The company relies on its patent portfolio to defend its product from similar offerings. It also emphasizes its proprietary chemistry and manufacturing processes, which it asserts are complex and require a highly specialized workforce to manage via external partners.
What growth costs
It incurs heavy, consistent costs in research, clinical development, and selling activities to sustain the drug's growth and test new applications.
Because the company is not currently profitable, it must invest substantial capital into ongoing clinical trials (such as LOTIS-5 and LOTIS-7) to validate the drug for earlier treatment lines. These R&D expenditures are mandatory for expanding its market, alongside significant ongoing marketing costs to drive physician awareness and adoption.
What could damage it
A failure to secure continued clinical trial success or regulatory approval would cripple its ability to expand ZYNLONTA into more lucrative patient populations.
Since the company has only one approved product, its financial viability is entirely dependent on ZYNLONTA. If clinical trials fail to prove efficacy for earlier treatment lines, or if regulatory bodies withdraw approval, the company would lose its sole path to generating revenue, leading to permanent impairment of its earnings potential.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.